BCL7A抑制了急性髓性白血病的进展和耐药性
Tushuai Li1, Renjie Gao2, Kaiwen Xu3
1Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, PR China; School of Biology and Food Engineering, Changshu Institute of Technology, Suzhou 215500, PR China.
概括
B细胞淋巴瘤7蛋白家族成员A (BCL7A) 作为急性髓性白血病 (AML) 的瘤抑制剂. 抑制BCL7A抑制AML的进展,并增强药物敏感性,提供新的治疗策略.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 急性髓性白血病 (AML) 仍然是血液瘤学的重大挑战.
- 了解驱动AML进展和耐药性的分子机制对于开发有效疗法至关重要.
研究的目的:
- 研究B细胞淋巴瘤7蛋白家族成员A (BCL7A) 在AML中的生物学作用和调节机制.
- 为了探索BCL7A和多聚胺系结合蛋白1 (PTBP1) 之间的相互作用.
- 评估BCL7A对AML进展和耐药性的影响.
主要方法:
- 对AML组织和细胞系中BCL7A表达的分析,与促进剂高甲基化相关.
- 在体外和体内研究检查BCL7A-PTBP1相互作用和BCL7A调制的影响.
- 评估BCL7A对细胞增殖,细胞亡,分化和淋巴结透的影响.
- 对BCL7A对干扰素调节因子7 (IRF7) 和HMGCS1.1的调节作用的评估.
主要成果:
- 在AML中,BCL7A的调控下降,主要是由于促进剂高甲基化和PTBP1.1的负调节.
- 在体内,BCL7A上调抑制了AML细胞生长,诱导了亡,促进了分化,并减少了淋巴结透.
- 过度表达BCL7A导致IRF7增加和HMGCS1降低,与AML恶性病和细胞因子抗性降低相关.
结论:
- 在AML中,BCL7A作为瘤抑制剂起作用,抑制恶性进展.
- 在AML中,BCL7A通过IRF7/HMGCS1通路增强药物敏感性.
- BCL7A代表了改善AML治疗结果的潜在治疗标.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K


